DPP4 and type 2 diabetes mellitus: The trial was prematurely halted after only 40% of subjects were enrolled because of concerns given recent guideline recommendations to preferentially use SGLT2 inhibitors, instead of DPP4 inhibitors, in patients with T2DM and HF, thus, significantly reducing the overall power of the study.